KA/EN
Register
Medicines reference
Search
Search
Active substance

Albumin (human)

Favourites

Plasma-derived colloid, blood product. Registered in Georgia: 6 human medicines. Forms: solution.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

Known Contraindications

  • Critical
    Repeat administration carries a separate and greater risk; always establish whether the patient has received human albumin previously. In a study of 9 healthy dogs given 25% human albumin, all 9 developed antibodies and 8 had a positive intradermal test. One dog had an anaphylactoid reaction during the first infusion; both of the 2 dogs that received a second infusion reacted. The first exposure can sensitize the patient.
  • Critical
    A reaction may be delayed, so an uneventful infusion does not establish safety. In a study of 6 healthy dogs, all 6 developed delayed reactions between days 5 and 13, including lethargy, lameness, oedema, cutaneous vasculitis, vomiting, and anorexia; 2 died despite treatment. Warn the owner about signs to watch for at home and monitor the patient weekly for at least 1 month. In a series of 73 critically ill dogs, 23% had at least one complication during or immediately after infusion and 4% had a severe delayed complication.
  • Critical
    Do not dilute with sterile water for injection as this may cause hemolysis in recipients. Do not add supplementary medication.
    Sources: FDA
  • Critical
    Severe anemia or cardiac failure with normal or increased intravascular volume.
    Sources: FDA
  • Critical
    Severe anemia or cardiac failure with normal or increased intravascular volume.
    Sources: FDA
  • Critical
    Hypersensitivity to albumin preparations or to any of the excipients.
    Sources: FDA
  • Warning
    Use with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.
    Sources: FDA
  • Warning
    Use cautiously in renal disease. Volume loading and haemodilution are both risks, and delayed type III hypersensitivity associated with acute kidney injury has been reported in 2 dogs. Monitor urine output during infusion and creatinine during the following weeks.
Latin name
Albumin (human)
Georgian name
ალბუმინი (ადამიანის)
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
6 of 6 forms
Products
Albuman, Albumin Uman, Albunorm, Alburex, SK Albumin, Zenalb
Human medicines in Georgia
Albuman, Albunorm, Alburex, Zenalb
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration6

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Albuman 20%, Solution

solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.9/10
Weak evidence support
vetman assessment

Albuman

20%, solution for infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-044172, რ-044173 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and EU/EEA with identifiable strength and manufacturer; exhaustive current checks record no exact GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy5.5/10

Hyperoncotic 25% HSA increased albumin, total protein and colloid osmotic pressure in retrospective canine septic-peritonitis data, without proving shorter stay or survival benefit. Applying that evidence to an exact 20% product is a concentration transfer; species-specific albumin remains preferred and treatment of the underlying protein loss is essential.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.6/10
Weak evidence support
vetman assessment

Albuman

20%, solution for infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-044172, რ-044173 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and EU/EEA with identifiable strength and manufacturer; exhaustive current checks record no exact GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy4.5/10

Cats have useful but uncontrolled 5% HSA data; evidence for direct hyperoncotic 20–25% treatment is sparse and does not establish an outcome advantage. Applying canine/review evidence to an exact 20% feline infusion is a substantial transfer, while species-specific feline albumin is unavailable and cause-directed care remains primary.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)200 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Prothya Biosolutions · Netherlands
Registration
Georgia Yes, human
In force until 21 Oct 2030
Human (Ministry of Health, RAMA)
In the register: ალბუმანი 20%, საინფუზიო ხსნარი
№ რ-044172, რ-044173
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Albumin Uman 20%, Solution

solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.9/10
Weak evidence support
vetman assessment

Albumin Uman

20%, solution for infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-041263, რ-041264 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and EU/EEA with identifiable strength and manufacturer; exhaustive current checks record no exact GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy5.5/10

Hyperoncotic 25% HSA increased albumin, total protein and colloid osmotic pressure in retrospective canine septic-peritonitis data, without proving shorter stay or survival benefit. Applying that evidence to an exact 20% product is a concentration transfer; species-specific albumin remains preferred and treatment of the underlying protein loss is essential.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.6/10
Weak evidence support
vetman assessment

Albumin Uman

20%, solution for infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-041263, რ-041264 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and EU/EEA with identifiable strength and manufacturer; exhaustive current checks record no exact GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy4.5/10

Cats have useful but uncontrolled 5% HSA data; evidence for direct hyperoncotic 20–25% treatment is sparse and does not establish an outcome advantage. Applying canine/review evidence to an exact 20% feline infusion is a substantial transfer, while species-specific feline albumin is unavailable and cause-directed care remains primary.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)200 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Kedrion · Italy
Registration
Georgia Yes, human
In force until 11 Jun 2029
Human (Ministry of Health, RAMA)
In the register: ალბუმინი უმან 20%, საინფუზიო ხსნარი
№ რ-041263, რ-041264
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Albunorm 5%, Solution

solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
6.0/10
Situational / acceptable
vetman assessment

Albunorm

5%, solution for infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-037378 · Verified on 15 Oct 2026 Off-label use

A situational ICU xenoprotein option when severe hypoalbuminaemia is causing clinical oncotic failure and species-specific albumin is unavailable. Five-percent evidence is more reassuring than hyperoncotic evidence but remains uncontrolled for outcome; obtain informed consent, monitor intensively, avoid routine numeric correction and arrange delayed immune follow-up.

Regulatory and scientific credibility6.5/10

The exact human product has sourced current registrations in Georgia, EU/EEA and GB, an identifiable plasma-derived composition and an accessible exact SmPC; current US checking records no exact registration. Veterinary use is off-label and human-product authorisation does not validate xenoprotein use in dogs or cats.

Clinical efficacy6.0/10

Five-percent HSA raised albumin in a retrospective series of 418 dogs and 170 cats, but the uncontrolled design, absent long-term follow-up and lack of a species-albumin comparator prevent a proven survival benefit. Current AAHA guidance allows HSA in selected dogs or cats while preferring species-specific albumin and noting that correction of albumin concentration has not been linked reliably to improved outcome.

Safety and tolerability5.5/10

Prospective follow-up found no clinical type-I or type-III hypersensitivity after controlled 5% HSA in 73 ill dogs and 40 ill cats, and the 588-patient retrospective series reported no severe in-hospital reaction. HSA nevertheless remains a foreign protein: other concentrations caused antibodies, anaphylactoid reactions, delayed vasculitis, organ injury and deaths, especially in healthy or repeat-exposed dogs; volume overload and human blood-product risks also require active control.

Clinical practicality6.0/10

The 5% solution is ready for a peripheral controlled infusion and matches the concentration used in the largest dog/cat series, but typical 20 ml/kg daily volumes, slow administration, continuous monitoring, single-use handling and delayed follow-up create substantial ICU workload and may be unsuitable in patients at risk of fluid overload.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • The reassuring veterinary evidence is tied to controlled 5% HSA in critically ill hypoalbuminaemic patients. Preserve the studied concentration, rate and monitoring context; absence of observed reactions does not establish safety for healthy animals, repeat exposure or rapid infusion.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
6.0/10
Situational / acceptable
vetman assessment

Albunorm

5%, solution for infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-037378 · Verified on 15 Oct 2026 Off-label use

A situational ICU xenoprotein option when severe hypoalbuminaemia is causing clinical oncotic failure and species-specific albumin is unavailable. Five-percent evidence is more reassuring than hyperoncotic evidence but remains uncontrolled for outcome; obtain informed consent, monitor intensively, avoid routine numeric correction and arrange delayed immune follow-up.

Regulatory and scientific credibility6.5/10

The exact human product has sourced current registrations in Georgia, EU/EEA and GB, an identifiable plasma-derived composition and an accessible exact SmPC; current US checking records no exact registration. Veterinary use is off-label and human-product authorisation does not validate xenoprotein use in dogs or cats.

Clinical efficacy6.0/10

Five-percent HSA raised albumin in a retrospective series of 418 dogs and 170 cats, but the uncontrolled design, absent long-term follow-up and lack of a species-albumin comparator prevent a proven survival benefit. Current AAHA guidance allows HSA in selected dogs or cats while preferring species-specific albumin and noting that correction of albumin concentration has not been linked reliably to improved outcome.

Safety and tolerability5.5/10

Prospective follow-up found no clinical type-I or type-III hypersensitivity after controlled 5% HSA in 73 ill dogs and 40 ill cats, and the 588-patient retrospective series reported no severe in-hospital reaction. HSA nevertheless remains a foreign protein: other concentrations caused antibodies, anaphylactoid reactions, delayed vasculitis, organ injury and deaths, especially in healthy or repeat-exposed dogs; volume overload and human blood-product risks also require active control.

Clinical practicality6.0/10

The 5% solution is ready for a peripheral controlled infusion and matches the concentration used in the largest dog/cat series, but typical 20 ml/kg daily volumes, slow administration, continuous monitoring, single-use handling and delayed follow-up create substantial ICU workload and may be unsuitable in patients at risk of fluid overload.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • The reassuring veterinary evidence is tied to controlled 5% HSA in critically ill hypoalbuminaemic patients. Preserve the studied concentration, rate and monitoring context; absence of observed reactions does not establish safety for healthy animals, repeat exposure or rapid infusion.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)50 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Octapharma · Switzerland
Registration
Georgia Yes, human
In force until 21 Feb 2028
Human (Ministry of Health, RAMA)
№ რ-037378
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL106730030, PL106730031, PL106730034, PL106730035
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Alburex 20%, Solution

solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
5.1/10
Weak evidence support
vetman assessment

Alburex

20%, solution for infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 5.1/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-038959, რ-038960 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.5/10

The exact human product has sourced current registrations in Georgia, EU/EEA and GB, an identifiable plasma-derived composition and an accessible exact SmPC; current US checking records no exact registration. Veterinary use is off-label and human-product authorisation does not validate xenoprotein use in dogs or cats.

Clinical efficacy5.5/10

Hyperoncotic 25% HSA increased albumin, total protein and colloid osmotic pressure in retrospective canine septic-peritonitis data, without proving shorter stay or survival benefit. Applying that evidence to an exact 20% product is a concentration transfer; species-specific albumin remains preferred and treatment of the underlying protein loss is essential.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.8/10
Weak evidence support
vetman assessment

Alburex

20%, solution for infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.8/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-038959, რ-038960 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.5/10

The exact human product has sourced current registrations in Georgia, EU/EEA and GB, an identifiable plasma-derived composition and an accessible exact SmPC; current US checking records no exact registration. Veterinary use is off-label and human-product authorisation does not validate xenoprotein use in dogs or cats.

Clinical efficacy4.5/10

Cats have useful but uncontrolled 5% HSA data; evidence for direct hyperoncotic 20–25% treatment is sparse and does not establish an outcome advantage. Applying canine/review evidence to an exact 20% feline infusion is a substantial transfer, while species-specific feline albumin is unavailable and cause-directed care remains primary.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)200 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
CSL Behring · United States
Registration
Georgia Yes, human
In force until 31 Aug 2028
Human (Ministry of Health, RAMA)
In the register: ალბურექსი 20%, საინფუზიო ხსნარი
№ რ-038959, რ-038960
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL150360031, PL150360032
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

SK Albumin 20%, Solution

solution for injection and infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.8/10
Weak evidence support
vetman assessment

SK Albumin

20%, solution for injection and infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.8/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-034794 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility5.5/10

The exact human product has a sourced current Georgian registration and identifiable strength and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy5.5/10

Hyperoncotic 25% HSA increased albumin, total protein and colloid osmotic pressure in retrospective canine septic-peritonitis data, without proving shorter stay or survival benefit. Applying that evidence to an exact 20% product is a concentration transfer; species-specific albumin remains preferred and treatment of the underlying protein loss is essential.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.5/10
Weak evidence support
vetman assessment

SK Albumin

20%, solution for injection and infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.5/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-034794 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility5.5/10

The exact human product has a sourced current Georgian registration and identifiable strength and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy4.5/10

Cats have useful but uncontrolled 5% HSA data; evidence for direct hyperoncotic 20–25% treatment is sparse and does not establish an outcome advantage. Applying canine/review evidence to an exact 20% feline infusion is a substantial transfer, while species-specific feline albumin is unavailable and cause-directed care remains primary.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)200 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
SK Plasma · South Korea
Registration
Georgia Yes, human
In force until 29 Mar 2027
Human (Ministry of Health, RAMA)
In the register: SK ალბუმინი 20%, საინექციო და საინფუზიო ხსნარი
№ რ-034794
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Zenalb 20 20%, Solution

solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.9/10
Weak evidence support
vetman assessment

Zenalb

20 20%, solution for infusion, human medicine
Assessed clinical scopeDog · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-037567, რ-037568 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and GB with identifiable strength and manufacturer; exhaustive current checks record no exact EU/EEA or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy5.5/10

Hyperoncotic 25% HSA increased albumin, total protein and colloid osmotic pressure in retrospective canine septic-peritonitis data, without proving shorter stay or survival benefit. Applying that evidence to an exact 20% product is a concentration transfer; species-specific albumin remains preferred and treatment of the underlying protein loss is essential.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure
4.6/10
Weak evidence support
vetman assessment

Zenalb

20 20%, solution for infusion, human medicine
Assessed clinical scopeCat · IV human albumin for severe or worsening hypoalbuminaemia with clinically important oedema, effusion or oncotic failure when species-specific albumin is unavailable and ICU risk-benefit assessment favours xenoprotein exposure · Intravenous
Care settingICU infusion with continuous cardiorespiratory and volume observation, serial albumin, haematocrit, electrolyte and urine-output checks, immediate reaction capability and delayed immune follow-up
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-037567, რ-037568 · Verified on 16 Oct 2026 Off-label use

A weak, specialist rescue option rather than routine albumin replacement. The exact 20% product is transparent as a human blood product, but veterinary benefit and dosing are extrapolated and hyperoncotic xenoprotein safety is concerning; prefer species-specific albumin in dogs, treat the cause, and do not copy a 5% volume regimen.

Regulatory and scientific credibility6.0/10

The exact human product has sourced current registrations in Georgia and GB with identifiable strength and manufacturer; exhaustive current checks record no exact EU/EEA or US registration. Its veterinary evidence is concentration/class evidence rather than an exact-product animal dossier.

Clinical efficacy4.5/10

Cats have useful but uncontrolled 5% HSA data; evidence for direct hyperoncotic 20–25% treatment is sparse and does not establish an outcome advantage. Applying canine/review evidence to an exact 20% feline infusion is a substantial transfer, while species-specific feline albumin is unavailable and cause-directed care remains primary.

Safety and tolerability3.5/10

This hyperoncotic human xenoprotein sits close to the 25% preparations associated with anti-HSA antibodies, acute reactions, delayed type-III disease and deaths in dogs. Exact 20% veterinary safety and repeat-exposure data are absent; severe anaemia, cardiac/renal vulnerability, capillary leak, sodium load, volume expansion and transfusion traceability materially constrain use.

Clinical practicality4.5/10

The small-volume 20% presentation is physically convenient but has no directly validated veterinary regimen. Individual calculation, possible aseptic dilution with compatible crystalloid, strict rate and haemodynamic monitoring, single-use wastage and weeks of delayed-reaction surveillance make it specialist-only and error-sensitive; the 5% ml/kg protocol cannot be copied directly.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use human albumin in a healthy or normoalbuminaemic animal, as a nutritional protein source, for routine crystalloid replacement or merely to normalize a laboratory albumin value. Restrict consideration to critical illness in which severe or worsening hypoalbuminaemia is causing clinically important oncotic consequences.
  • Establish any previous human-albumin exposure before treatment. Dogs develop anti-human-albumin antibodies, and repeat infusion may provoke a more severe acute or delayed reaction; avoid repeat exposure unless a compelling life-saving benefit clearly outweighs this risk.
  • Be prepared to stop the infusion and treat anaphylaxis immediately. Warn the owner about delayed type-III disease 5–13 days later—fever, lethargy, lameness, oedema, vomiting, skin lesions or vasculitis—and arrange surveillance for at least four weeks; fatal canine cases are reported.
  • Prefer species-specific albumin for dogs when it is genuinely available. Human serum albumin is a xenoprotein in dogs and cats; document the rescue rationale and informed-owner discussion rather than presenting human-product availability as evidence of veterinary equivalence.
  • Treat the cause of albumin loss or reduced synthesis and define a clinical endpoint such as improving oedema, effusion, perfusion or oncotic status. A higher serum albumin concentration is a surrogate; available veterinary studies do not prove that numeric correction alone improves survival.
  • Individualize dose and rate from volume status and ongoing losses, not serum albumin alone. Monitor blood pressure, pulse, respiration, urine output, electrolytes, haematocrit/haemoglobin and signs of pulmonary or peripheral fluid overload throughout infusion.
  • Do not infuse in severe anaemia or cardiac failure with normal or increased intravascular volume. Use exceptional caution with renal disease, capillary leak or any state in which hypervolaemia, haemodilution or sodium load can worsen organ function.
  • Never dilute human albumin with sterile water because haemolysis may result. Use only a compatible isotonic diluent when dilution is required; do not mix the product with other medicinal products, whole blood or packed red cells in the same container or line.
  • Record the exact product and batch, inspect the solution, maintain asepsis and discard unused single-use remainder. Donor screening and viral inactivation reduce but cannot eliminate transmission of known, emerging or unknown agents from a human plasma-derived product.
  • No directly validated dog or cat regimen exists for this exact 20% concentration. Do not copy the 5% ml/kg volume: 20% contains four times as much albumin per millilitre. Direct hyperoncotic use or dilution requires an ICU specialist calculation; 20–25% xenoprotein evidence includes serious delayed immune injury.
Assessment sources
  1. Human albumin market audit2026
  2. Albunorm 5% SmPC2023
  3. Alburex 20 SmPC2018
  4. AAHA fluid therapy 20242024
  5. 5% HSA in 588 patients2010
  6. Viganó et al. 20192019
  7. Viganó et al. 20222022
  8. Cohn et al. 20072007
  9. Francis et al. 20072007
  10. 25% HSA in septic peritonitis2015
  11. 25% HSA risk-benefit review2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Albumin (human)200 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Bio Products Laboratory · United Kingdom
Registration
Georgia Yes, human
In force until 15 Mar 2028
Human (Ministry of Health, RAMA)
In the register: ზენალბი 20 20%, საინფუზიო ხსნარი
№ რ-037567, რ-037568
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK Yes, human
№ PL088010006
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗